Global Geriatric Medicines Market Surges Toward US$ 1142.8 Billion by 2027, Enhancing the Quality of Senior Healthcare - TMR Study

Geriatric Medicines market is estimated to attain a valuation of US$ 1142.8 Billion by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6.9% during the forecast period, 2022-2027

The Global Geriatric Medicines Market is a vital and growing sector within the pharmaceutical and healthcare industries, focusing on medications and healthcare solutions specifically designed for the elderly population. As the world's elderly population continues to increase, the demand for geriatric medicines to address age-related health issues and improve the quality of life for older adults is on the rise. This research report provides a comprehensive analysis of the Global Geriatric Medicines Market, covering market dynamics, trends, growth drivers, challenges, and the competitive landscape.

Get a Sample Copy of the Geriatric Medicines Market Research Report (Use Corporate Mail Id for Quick Response) -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2445

"Connect with our team of research specialists and unlock the optimal solution for driving your business growth"

Market Trends

• Polypharmacy Management
Efforts to reduce polypharmacy and minimize the number of medications prescribed to older adults while maintaining therapeutic efficacy.
• Personalized Medicine
The adoption of personalized medicine approaches for geriatric patients, tailoring treatments based on individual health profiles.
• Telemedicine and Remote Monitoring
The use of telemedicine and remote monitoring to provide healthcare services and monitor the health of elderly patients, especially during the COVID-19 pandemic.

Market Drivers

• Aging Population
The global increase in the elderly population is a primary driver for the Geriatric Medicines Market.
• Age-Related Diseases
The higher incidence of age-related diseases, such as cardiovascular diseases and diabetes, necessitates the development and use of geriatric medicines.

Market Challenges

• Polypharmacy
Managing multiple medications for elderly patients can lead to complications, including drug interactions and adverse effects.
• Healthcare Access
Ensuring access to geriatric medicines and healthcare services for elderly populations, particularly in underserved areas, can be challenging.

Inquire more about this report before purchase - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=2445

The report covers extensive competitive intelligence which includes the following data points:

- Business Overview
- Business Model
- Financial Data
- Financial - Existing
- Financial - Funding
- Product/Service Segment Analysis and specification
- Recent Development and Company Strategy Analysis
- SWOT Analysis

Competitor Analysis:

The significant players operating in the global Geriatric Medicines market are

Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Novartis AG

Market Segmentation -

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2022-2027.

This Report lets you identify the opportunities in Geriatric Medicines Market by means of a region:

• North America (the United States, Canada, and Mexico)
• Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
• Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
• South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

Have Any Query? Ask To Analyst: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=2445

Recent Developments

Here are some recent developments of companies in the Geriatric Medicines Market, with the year:

year: 2023

• AstraZeneca (UK) announced the launch of its new drug, Imfinzi, for the treatment of advanced non-small cell lung cancer in elderly patients.
• Merck & Co. (US) announced the launch of its new drug, Keytruda, for the treatment of melanoma in elderly patients.
• Pfizer (US) announced the acquisition of Biohaven Pharmaceutical Holding Company (US), a company developing drugs for Alzheimer's disease, migraine, and other neurological disorders.

year: 2022

• Novartis (Switzerland) announced the launch of its new drug, Leqvio, for the treatment of Alzheimer's disease in early stages.
• Eli Lilly and Company (US) announced the launch of its new drug, Donanemab, for the treatment of Alzheimer's disease in early stages.
• Eisai Co., Ltd. (Japan) announced the launch of its new drug, Lecanemab, for the treatment of Alzheimer's disease in early stages.

Reasons to Buy The Geriatric Medicines Market Report: -

1.Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.

2.Reports provide opportunities and threats faced by suppliers in the Geriatric Medicines industry around the world.

The report shows regions and sectors with the fastest growth potential.

3.A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.

4.The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.

5.This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

More Trending Reports by Transparency Market Research -

Orthobiologics Market - https://www.globenewswire.com/news-release/2023/04/18/2649014/0/en/Orthobiologics-Market-Revenue-to-Cross-USD-13-8-Bn-by-2031-Transparency-Market-Research.html

ePharmacy Market- https://www.globenewswire.com/en/news-release/2023/04/21/2651813/0/en/ePharmacy-Market-Revenue-to-Cross-USD-362-8-Bn-by-2031-with-CAGR-of-19-2-TMR-Study.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.